Cure My Disease

Don't miss your cure!

 Log in / Sign up

Yale researchers scan brains to see how THC impairs memory

NCT ID NCT06647524

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how THC, the active ingredient in cannabis, temporarily affects memory, learning, and balance in adults aged 21 to 55 who have used cannabis before. Ten participants will complete memory tasks and balance tests inside an fMRI scanner after taking either THC or a placebo. The goal is to understand how THC changes brain activity and thinking, which may help explain age-related effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CNB use within past 2 years and felt "high" when used. * Able to read, speak, and understand English. * Able and willing to provide written informed consent, and willing to commit to the study protocol. Exclusion Criteria: * Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence. * Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment * History of adverse effects with CNB * CNB users who are abstaining * IQ \<80 on the Wechsler Abbreviated Scale of Intelligence * Inability to comprehend written instructions using the WRAT 4 reading achievement test * Pregnant, breastfeeding, and ineffective birth control methods * Unable or unsafe to have an MRI * Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy * History of head trauma with loss of consciousness \> 30 minutes or concussion lasting 30 days * Focal brain lesion seen on structural MRI * Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome) * Anyone deemed unsafe to study personnel for any reason * Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study * Significant pain and/or reduced mobility in the arms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Memory Disorders thrombocytopenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Olin Neuropsychiatric Research Center at Hartford Healthcare

    RECRUITING

    Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.